Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Björkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):1057-64. Epub 2005 Mar 10.

2.

Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.

Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BF, Wolfe ML, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ.

J Lipid Res. 2009 Jul;50(7):1456-62. doi: 10.1194/jlr.P800037-JLR200. Epub 2009 Feb 3.

3.

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.

Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.

Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1350-6. Epub 2006 Mar 30.

4.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.

N Engl J Med. 2004 Apr 8;350(15):1505-15.

5.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10.

6.

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.

Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Cohn JS, Wilson A, Wolfe ML, Nartsupha C, Schaefer PM, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.

J Lipid Res. 2008 Mar;49(3):543-9. Epub 2007 Nov 21.

8.

HDL metabolism and CETP inhibition.

Barkowski RS, Frishman WH.

Cardiol Rev. 2008 May-Jun;16(3):154-62. doi: 10.1097/CRD.0b013e31816a3b60.

PMID:
18414186
9.

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1132-8. Epub 2007 Feb 22.

10.

Effect of torcetrapib on the progression of coronary atherosclerosis.

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators.

N Engl J Med. 2007 Mar 29;356(13):1304-16. Epub 2007 Mar 26. Erratum in: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P].

11.

Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.

Schaefer EJ, Asztalos BF.

Curr Opin Lipidol. 2006 Aug;17(4):394-8. Review.

PMID:
16832162
12.

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.

Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ.

Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7. Epub 2004 Jan 22.

13.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.

Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum in: Circulation. 2009 Feb 10;119(5):e197.

14.

Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.

Diffenderfer MR, Brousseau ME, Millar JS, Barrett PH, Nartsupha C, Schaefer PM, Wolfe ML, Dolnikowski GG, Rader DJ, Schaefer EJ.

J Lipid Res. 2012 Jun;53(6):1190-9. doi: 10.1194/jlr.M019570. Epub 2012 Apr 2.

15.

Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.

Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.

Eur J Pharmacol. 2014 Oct 5;740:135-43. doi: 10.1016/j.ejphar.2014.06.022. Epub 2014 Jul 5.

PMID:
25008069
16.

CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.

Briand F, Thieblemont Q, André A, Ouguerram K, Sulpice T.

Clin Transl Sci. 2011 Dec;4(6):414-20. doi: 10.1111/j.1752-8062.2011.00344.x. Epub 2011 Dec 7.

18.

Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.

Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, Krueger KA.

Am J Cardiol. 2014 Jun 15;113(12):2021-9. doi: 10.1016/j.amjcard.2014.03.045. Epub 2014 Apr 2.

19.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators.

N Engl J Med. 2007 Apr 19;356(16):1620-30. Epub 2007 Mar 26.

20.

Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.

Zareba G.

Drugs Today (Barc). 2006 Feb;42(2):95-102.

PMID:
16541186

Supplemental Content

Support Center